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A membrane receptor and a cytosolic receptor for somatostatin were found in a human undifferentiated 
pancreatic ancer cell line (MIA PaCa-2). Binding of somatostatin to this membrane receptor activates de- 
phosphorylation of a phosphotyrosyl-membrane protein whose phosphorylation was promoted by epider- 
ma1 growth factor (EGF). Vanadate, a purported inhibitor of dephosphorylation, interferes with the action 
of somatostatin. These findings suggest a possible biochemical mechanism by which somatostatin may in- 
hibit the growth of human pancreatic ancers. 
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1. INTRODUCTION 
The existence of low-M, peptide hormones 
which stimulate cell growth and proliferation is 
well documented [ 1,2]. Conversely, little is known 
about hormones or growth inhibiting factors 
which have antiproliferative effects on the cell. Re- 
cent studies indicate that one of these antiprolifer- 
ative factors could be somatostatin, a ubiquitous 
neuropeptide which inhibits numerous cellular 
processes [3-51. For instance, it was recently 
demonstrated that somatostatin inhibited EGF- 
induced centrosomal separation, DNA synthesis, 
and cell replication in HeLa cells [6]. Inhibition of 
growth of pancreatic carcinoma in animal models 
by analogs of somatostatin was also recently de- 
monstrated [7]. 
The report that somatostatin-14 stimulates cyto- 
plasmic PPPase (phosphoprotein phosphatase) in 
Abbreviations: SS, somatostatin; EGF, epidermal 
growth factor 
normal pancreas [8] prompted us to study the ef- 
fect of somatostatin on dephosphorylation of 
membrane proteins in the MIA PaCa-2 cells from 
human pancreatic adenocarcinoma. Here, we spe- 
cifically concentrated on the relation of somatosta- 
tin and its receptor to EGF receptor phosphoryla- 
tion-dephosphorylation process. The EGF recep- 
tor is a 170-kDa membrane glycoprotein that con- 
tains intrinsic tyrosine kinase activity. 
2. MATERIALS AND METHODS 
2.1. Cell culture 
The MIA PaCa-2 cell line [9], a human pan- 
creatic carcinoma cell line, was obtained from 
American Tissue Type Cultures. The cells were 
grown in Dulbecco’s modified Eagle’s medium 
containing 10% fetal calf serum and 2.5% horse 
serum. Cells were incubated at 37°C in humidified 
air containing 5% COZ. Cells were harvested using 
0.1% trypsin in phosphate-buffered saline. Mem- 
brane vesicles from MIA PaCa-2 cells were pre- 
pared as in [lo]. 
252 
Published by Elsevier Science Publishers B. V. (Biomedical Dwision) 
00145793/85/$3.30 0 1985 Federation of European Biochemical Societies 
Volume 179, number 2 FEBS LETTERS 
2.2. Somatostatin binding to its receptor 
[‘251]Iodo-Tyr’-somatostatin (Peninsula) was 
prepared by chloramine-T iodination. One micro- 
gram of Tyrr-somatostatin in 25 ~1 of 0.01 N acetic 
acid was added to 50~1 of 0.5 M phosphate buf- 
fer, pH 7.5, containing 2.0 mCi carrier-free 
Na’*‘I. After addition of 1 pg chloramine-T, the 
mixture was agitated for 90 s and the reaction was 
terminated by the addition of 100~1 saturated 
tyrosine solution. The labelled somatostatin was 
purified by chromatography on Biogel P-2 column 
and eluted with 0.01 N acetic acid containing 0.1% 
BSA. The specific activity of the labelled material 
determined by radioligand receptor assay ranged 
from 1100 to 1900&i/g. The [1251]iodo-Tyr’ - 
somatostatin tracer was stored in aliquots at 
- 10°C and was stable for at least 1 month. 
2.3. Somatostatin binding assay 
Aliquots of the membrane suspension contain- 
ing 50-100 pug protein were incubated in 500 ~1 of 
50 mM Tris-HCl buffer, pH 7.4, containing 
5 mM MgC12, 2 mM EGTA, 20pg/ml ethylmer- 
curithiosalicylate (Thimerosal) (Sigma, St. Louis, 
MO) and 50 pg/ml bacitracin for 90 min at 16°C. 
After incubation, the receptor-bound and free 
radioactivity were separated by filtration using 
Whatman 6F/C glass fiber filters (Whatman, Clif- 
ton, NJ). Filters were washed 3 times with 4 ml 
cold phosphate-buffered saline (PBS) and the 
bound radioactivity was measured in a Beckman 
Gamma-spectrometer. The degradation of cold 
and labelled somatostatin during the binding assay 
was measured as described [l 11. Specific binding 
was estimated as a difference between ‘total’ bind- 
ing (i.e., in the presence of a tracer alone) and 
‘non-specific’ binding which was measured in the 
presence of lo-’ M unlabelled somatostatin. 
Specific binding represented l-3% of the total 
radioactivity. Non-specific binding accounted for 
15-20% of total binding. 
2.4. Miscellaneous 
Phosphoprotein phosphatase activity was meas- 
ured by the release of 32P from ‘*P-1abelled sub- 
strates at 37°C. Reaction mixture for the PPPase 
activities was determined as detailed using “P-la- 
belled calf thymus type II-S histone (32P-histone) 
as exogenous ubstrate [12]. Purification of phos- 
phoprotein-phosphatase from rat pancreas was 
carried out as described ]131. 
3. RESULTS 
January 1985 
3.1. Binding of ‘Z51-Tyr’-somatostatin-14 to the 
membranes and cytosolic fractions from MIA 
PaCa-2 cells 
The specific binding of tracer was dependent 
upon incubation time and protein concentration. 
Maximal equilibrium level of tracer binding was 
found at 15 min for both cytosolic and membrane 
fraction. The optimal protein concentration was 
found to be 15Opg and further increases in the 
protein concentration had little effect on the 
nonspecific binding. The addition of increased 
concentration of unlabelled somatostatin-14 to the 
incubation mixture resulted in a progressive inhibi- 
tion of tracer binding (fig.l), indicating the pre- 
sence of a finite number of sites of competition be- 
tween labelled and unlabelled tracer. The amount 
of tracer bound per mg membrane proteins was 
3.6 + 0.4 fmol. The cytosolic sites were substan- 
tially more dense than the membrane sites, with 
0 -12 -10 -8 -6 
SOMATOSTATIN [Log M ] 
Fig.1, Specific binding of ‘2sI-Tyr’-somatostatin-14 to 
membranes from MIA PaCa-2 cells. Isolated mem- 
branes were incubated with radioactive tracer in the 
presence of various concentrations of unlabelled soma- 
tostatin-14. Mean values + SE of 3 experiments. 
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38.0 + 0.6 fmol tracer bound per mg cytosolic pro- 
tein (not shown). Since cytosolic fraction re- 
presents about 35% of cellular proteins and mem- 
brane fraction only 4-59’0 [ 131, there appear to be 
almost two orders of magnitude more cytosolic 
than membranous binding sites. Consequently, the 
role of cytosolic phosphoprotein-phosphatases in 
dephosphorylation of membrane proteins cannot 
be excluded. 
3.2. Stimulation by somatostatin of phospho- 
protein phosphatases in membranes from 
MIA PaCa-2 ceils 
To study the influence of somatostatin on 
phosphoprotein phosphatases in plasma mem- 
branes, we used as a substrate synthetic phospho- 
Tyr-histones and phospho-Ser-histones prepared 
as in [14]. Phosphatase activity is present in MIA 
PaCa-2 cell membrane, for both phospho-Tyr- 
histones and phospho-Ser-histones, but only 
phospho-Tyr-histones dephosphorylation is en- 
hanced by somatostatin (fig.2). These data suggest 
that the membranes contain phosphotyrosine spe- 
cific phosphatase different from phosphoserine 
specific protein phosphatase and that only the 
former is stimulated by somatostatin (fig.2). Phos- 
phoprotein-phosphatase, isolated and partially 
purified from rat pancreas, is also specific as 
> PHOSPHO-TYR-HISTONE 
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Fig.2. Effect of somatostatin on dephosphorylation of 
phospho-Tyr-histones and phospho-Ser-histones by 
membranes from MIA PaCa-2 cells (A , l ) and purified 
rat pancreatic cytosolic PPPase (X , 0). Protein phos- 
phatase activity was measured in the presence of various 
concentrations of somatostatin using phospho-Tyr- 
histone (0.20 gM ‘*P) (0, l ) or phospho-Ser-histone 
(0.48 gM 32P) (A , x). 
phosphoprotein-phosphatase from MIA PaCa-2 
cell membrane for these two phosphorylated sub- 
strates. 
Somatostatin caused dephosphorylation of 
membrane proteins which were previously en- 
zymatically phosphorylated in the presence of EGF 
in a manner analogous to the dephosphorylation 
of the synthetic phosphorylated tyrosine and serine 
substrates (fig.3). The stimulatory effect of soma- 
tostatin on dephosphorylation of endogenous MIA 
1234 56 78 
Fig.3. An autoradiograph of an SDS-PAGE showing the 
dephosphorylation of MIA PaCa-2 membrane proteins 
in the presence of 10-s M somatostatin (lanes 1, 3, 5, 7) 
and without somatostatin (controls) (lanes 2, 4, 6, 8). 
The results are shown as a function of incubation time: 
Lanes 1 and 2,10 min; lanes 3 and 4,20 min; lanes 5 and 
6, 30 min; lanes 7 and 8, 60 min. Aliquots of MIA 
PaCa-2 membranes were phosphorylated by incubation 
at 0°C in 20 mM Hepes buffer, pH 7.5, containing 
20 pM [y-32P]ATP, 2 mM MnCl2 and 0.5 gg/ml of EGF 
in a total volume of 100 pl. After 15 min, an aliquot was 
removed and unlabelled ATP (8OOpM) and IO-’ M 
somatostatin were added. In control experiments, 
somatostatin was omitted. The incubation was con- 
tinued at 0°C and aliquots were removed at 10, 20, 30 
and 60 min and added to a buffer solution containing 
0.2 M DTT 6% SDS and 25% glycerol in 50 mM 
Tris-Cl, pH 7.5. Electrophoresis was carried out in 10% 
polyacrylamide gel as in [17]. Autoradiography of the 
stained dried gel was carried out overnight at - 70°C in 
DuPont Cronex cassettes with intensifying screens using 
DuPont X-ray film. 
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PaCa-2 membrane proteins was measured as fol- 
lows: the membranes were phosphorylated with 
[Y-~~P]ATP in the presence of EGF and then the 
rates of dephosphorylation were measured (in the 
presence of an excess of non-radioactive ATP to 
prevent the reincorporation of labelled phosphate) 
in the presence or absence of lo-* M somatostatin- 
14. Fig.3 shows that he dephosphorylation of 
phosphoprotein band of 170 kDa (which repre- 
sents the EGF receptor with the protein kinase do- 
main) was markedly stimulated in the presence of 
somatostatin-14 and that the dephosphorylation 
increased with the time of incubation. 
3.3. The influence of vanadate on the stimulatory 
effect of somatostatin on dephosphorylation 
of membrane proteins from MIA PaCa-2 
cells 
To determine the effect of vanadate on somato- 
statin-stimulated dephosphorylation of membrane 
proteins from MIA PaCa-2 cells, the membranes 
were phosphorylated with [y-32P]ATP in the 
presence or absence of EGF and lo-* M somato- 
statin as indicated (fig.4). Vanadate (10pM) was 
added to the incubation mixture in combination 
with the EGF and somatostatin. The incorporation 
of 32P from 32P-labelled ATP was measured as 
described in fig.2. The mixture, consisting of 
24 I 
0 2 4 6 8 10 MIN 
Fig.4. The effects of EGF, somatostatin and vanadate in 
combination on the protein kinase activity in MIA 
PaCa-2 cell membranes. Incubation mixtures and 
conditions are described in the text. 
20 mM Hepes buffer, pH 7.5, 15 M [Y-~~P]ATP, 
1 mM MnCl2 and aliquots of membranes from 
MIA PaCa-2 cells in a final volume of 80~1, was 
incubated for various times. 
Vanadate could increase the level of phosphoty- 
rosine in the cellular phosphoproteins by inhibiting 
phosphotyrosyl-protein phosphatase. In contrast, 
somatostatin stimulated phosphotyrosine phos- 
phatase and decreased the level of phosphotyrosine 
in the cellular phosphoprotein. The resulting in- 
activation of tyrosine kinase nullified the prolifera- 
tion and growth stimuated by EGF. The 
phosphorylated membrane proteins were incu- 
bated with 10e8 M somatostatin and increasing 
amounts of purified cytosolic rat PPPase in the 
presence or absence of 10 /cM vanadate (fig.5). The 
percentage of Pi released from phosphorylated 
membrane proteins was dependent on the amount 
of purified cytosolic rat PPPase added. The mem- 
brane-bound PPPase was inhibited by 10,~M of 
vanadate. 
‘“lT---- 
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Fig.5. The effect of vanadate (10pM) on dephosphory- 
lation of membrane proteins in the presence of lo-* M 
somatostatin. Varying amounts of purified rat cytosolic 
PPPase were incubated with phosphorylated membrane 
protein and somatostatin in the presence (0) or absence 
(0) of 10pM vanadate. The percentage of labelled 
phosphate retained by the protein is plotted. 
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4. DISCUSSION 
This study examines the relationship of EGF, 
somatostatin and vanadate on the process of net 
phosphorylation of the EGF receptor from human 
pancreatic cancer. The EGF receptor has 3 func- 
tional domains: an EGF binding site located on the 
external cell surface, and transmembrane and 
cytoplasmic tyrosine kinase domains. Adenosine 
triphosphate is a donor for phosphorylation of in- 
tracellular substrates by the kinase. Phosphoryla- 
tion of EGF receptor at tyrosine residues plays an 
important role in regulation of cellular prolifera- 
tion and growth of normal tissue. Other human 
growth factors also regulate cell proliferation 
through the process of phosphorylation. Somato- 
statin nullifies the growth stimulation produced by 
EGF and potentiated by vanadate. Vanadate ir,- 
hibits a phosphotyrosine specific protein phos- 
phatase, which results in a synergistic effect of 
vanadate and EGF on DNA synthesis in human 
fibroblast [ 151. 
Our work shows that somatostatin reverses the 
stimulatory effect of EGF on phosphorylation of 
the tyrosine-kinase domain of the EGF-receptor. 
This suggests that the antagonistic effect of soma- 
tostatin on EGF is mediated directly through the 
phosphorylated product. Evidence exists that 
somatostatin inhibits cell growth in tissue cultures 
[6]. Preliminary evidence has suggested that soma- 
tostatin analogues also may be capable of in- 
hibiting the growth of exocrine pancreatic cancers 
in animal models [7]. Our results might explain 
how such inhibition could be mediated. The an- 
tagonistic effect of EGF and somatostatin on the 
EGF receptor phosphorylation and the presence of 
EGF and somatostatin receptors on the mem- 
branes of a human pancreatic adenocarcinoma 
suggest a potential biochemical mechanism for 
mediating this control of growth. 
The site of action of somatostatin on the mem- 
brane in addition to postmembrane and cytosolic 
located mechanisms indicate the remarkable 
plurality of binding sites of this hormone in the 
MIA PaCa-2 cell line (unpublished). The multi- 
plicity of somatostatin binding sites and the 
widespread distribution of similar sites in the 
body, together with antiproliferative effects of 
somatostatin (e.g., on HeLa cells [6]), suggest that 
somatostatin may belong to a class of hormones 
that act as endogenous growth inhibitors [16]. 
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Preliminary studies in tissue culture of MIA 
PaCa-2 cells demonstrate that EGF stimulates 
human pancreatic adenocarcinoma cell growth. 
The antiproliferative properties of somatostatin 
are under investigation (unpublished). The rela- 
tionship between EGF and somatostatin found in 
this work in human pancreatic adenocarcinoma 
cell line suggests a potential clinical application for 
somatostatin. If this interaction truly regulates 
cellular growth in situ, the receptor found in this 
pancreatic adenocarcinoma may have counterparts 
in other tumors. Attempts could then be made to 
inhibit pancreatic cancer growth by modern 
analogs of somatostatin. 
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